Ghafouri-Fard Soudeh, Shirvani-Farsani Zeinab, Taheri Mohammad
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Cellular and Molecular Biology, Faculty of Life Sciences and Technology, Shahid Beheshti University G.C., Tehran, Iran.
Noncoding RNA Res. 2020 Jun 20;5(3):88-98. doi: 10.1016/j.ncrna.2020.06.001. eCollection 2020 Sep.
Thyroid cancer is the most frequent type of cancers originating from the endocrine system. Early diagnosis leads to good clinical outcome in differentiated types of thyroid cancer. Yet, there are few treatment options for patients with medullary or anaplastic thyroid cancer. Thus, identification of molecular markers that explain the pathologic process during evolution of this cancer has practical significance. MicroRNAs (miRNAs) have been shown to influence the activity of thyroid cancer-related signaling pathways such as MAPK pathway and gene. These small transcripts not only can differentiate malignant tissues from non-malignant tissues, but also have differential expression in different stages of thyroid cancer. Assessment of serum levels of miRNAs is a practical noninvasive method for follow-up of patients after thyroidectomy. Moreover, the therapeutic effects of a number of miRNAs have been verified in xenograft models of thyroid cancer. In the current review, we summarize the data regarding the role of miRNAs in thyroid cancer.
甲状腺癌是源自内分泌系统的最常见癌症类型。早期诊断可使分化型甲状腺癌获得良好的临床结果。然而,对于髓样或未分化型甲状腺癌患者,治疗选择很少。因此,鉴定能够解释该癌症演变过程中病理过程的分子标志物具有实际意义。微小RNA(miRNA)已被证明可影响甲状腺癌相关信号通路(如MAPK通路)的活性和基因。这些小转录本不仅可以区分恶性组织和非恶性组织,而且在甲状腺癌的不同阶段具有差异表达。评估血清miRNA水平是甲状腺切除术后患者随访的一种实用非侵入性方法。此外,一些miRNA的治疗效果已在甲状腺癌异种移植模型中得到验证。在本综述中,我们总结了有关miRNA在甲状腺癌中作用的数据。